Arylmethylene Hydrazine Derivatives Containing 1,3-dimethylbarbituric Moiety As Novel Urease Inhibitors

Overview

Journal Sci Rep

Specialty Science

Date 2021 May 20

PMID 34012008

Citations 8

Authors

Keyvan Pedrood

Homa Azizian

Mohammad Nazari Montazer

Maryam Mohammadi-Khanaposhtani

Mohammad Sadegh Asgari

Mehdi Asadi

Saeed Bahadorikhalili

Hossein Rastegar

Bagher Larijani

Massoud Amanlou

Mohammad Mahdavi

Affiliations

Soon will be listed here.

Abstract

A new series of arylmethylene hydrazine derivatives bearing 1,3-dimethylbarbituric moiety 7a-o were designed, synthesized, and evaluated for their in vitro urease inhibitory activity. All the title compounds displayed high anti-urease activity, with IC values in the range of 0.61 ± 0.06-4.56 ± 0.18 µM as compared to the two standard inhibitors hydroxyurea (IC = 100 ± 0.15 μM) and thiourea (IC = 23 ± 1.7 μM). Among the synthesized compounds, compound 7h with 2-nitro benzylidene group was found to be the most potent compound. Kinetic study of this compound revealed that it is a mix-mode inhibitor against urease. Evaluation of the interaction modes of the synthesized compounds in urease active site by molecular modeling revealed that that compounds with higher urease inhibitor activity (7h, 7m, 7c, 7l, 7i, and 7o, with IC of 0.61, 0.86, 1.2, 1.34, 1.33, 1.94 μM, respectively) could interact with higher number of residues, specially Arg609, Cys592 (as part of urease active site flap) and showed higher computed free energy, while compounds with lower urease activity (7f, 7n, 7g, and 7a with IC of 3.56, 4.56, 3.62 and 4.43 μM, respectively) and could not provide the proper interaction with Arg609, and Cys592 as the key interacting residues along with lower free binding energy. MD investigation revealed compound 7h interacted with Arg609 and Cys592 which are of the key residues at the root part of mobile flap covering the active site. Interacting with the mentioned residue for a significant amount of time, affects the flexibility of the mobile flap covering the active site and causes inhibition of the ureolytic activity. Furthermore, in silico physico-chemical study of compounds 7a-o predicted that all these compounds are drug-likeness with considerable orally availability.

Citing Articles

Efficient synthesis of novel phenanthroline-dimedone derivatives using Pd@HQBI-SPION as a versatile palladium-immobilized catalyst.

Sayahi M, Serajian A, Bahadorikhalili S, Mahdavi M Sci Rep. 2024; 14(1):26325.

PMID: 39487194 PMC: 11530668. DOI: 10.1038/s41598-024-76221-3.

Synthesis, Urease Inhibition, Molecular Docking, and Optical Analysis of a Symmetrical Schiff Base and Its Selected Metal Complexes.

Bonne S, Saleem M, Hanif M, Najjar J, Khan S, Zeeshan M Molecules. 2024; 29(20).

PMID: 39459267 PMC: 11510561. DOI: 10.3390/molecules29204899.

Clodronic Acid has Strong Inhibitory Interactions with the Urease Enzyme of : Computer-aided Design and Confirmation.

Karami Fath M, Khalili S, Boojar M, Hashemi Z, Zarei M Curr Comput Aided Drug Des. 2023; 20(7):1100-1112.

PMID: 37957909 DOI: 10.2174/0115734099271837231026064439.

[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as new therapeutic candidates against urease positive microorganisms: design, synthesis, pharmacological evaluations, and in silico studies.

Khalili Ghomi M, Noori M, Nazari Montazer M, Zomorodian K, Dastyafteh N, Yazdanpanah S Sci Rep. 2023; 13(1):10136.

PMID: 37349372 PMC: 10287669. DOI: 10.1038/s41598-023-37203-z.

Synthetic Transformation of 2-{2-Fluoro[1,1'-biphenyl]-4-yl} Propanoic Acid into Hydrazide-Hydrazone Derivatives: Urease Inhibition and Study.

Ahmad S, Khan M, Shah M, Ali M, Alam A, Riaz M ACS Omega. 2022; 7(49):45077-45087.

PMID: 36530251 PMC: 9753537. DOI: 10.1021/acsomega.2c05498.

References

Hifumi E, Morihara F, Hatiuchi K, Okuda T, Nishizono A, Uda T . Catalytic features and eradication ability of antibody light-chain UA15-L against Helicobacter pylori. J Biol Chem. 2007; 283(2):899-907. DOI: 10.1074/jbc.M705674200. View

de Fatima A, Pereira C, Olimpio C, de Freitas Oliveira B, Franco L, da Silva P . Schiff bases and their metal complexes as urease inhibitors - A brief review. J Adv Res. 2018; 13:113-126. PMC: 6077242. DOI: 10.1016/j.jare.2018.03.007. View

Rauf A, Shahzad S, Bajda M, Yar M, Ahmed F, Hussain N . Design and synthesis of new barbituric- and thiobarbituric acid derivatives as potent urease inhibitors: Structure activity relationship and molecular modeling studies. Bioorg Med Chem. 2015; 23(17):6049-58. DOI: 10.1016/j.bmc.2015.05.038. View

Azizian H, Mousavi Z, Faraji H, Tajik M, Bagherzadeh K, Bayat P . Arylhydrazone derivatives of naproxen as new analgesic and anti-inflammatory agents: Design, synthesis and molecular docking studies. J Mol Graph Model. 2016; 67:127-36. DOI: 10.1016/j.jmgm.2016.05.009. View

Pires D, Blundell T, Ascher D . pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015; 58(9):4066-72. PMC: 4434528. DOI: 10.1021/acs.jmedchem.5b00104. View

Azizian H, Nabati F, Sharifi A, Siavoshi F, Mahdavi M, Amanlou M . Large-scale virtual screening for the identification of new Helicobacter pylori urease inhibitor scaffolds. J Mol Model. 2011; 18(7):2917-27. DOI: 10.1007/s00894-011-1310-2. View

Lacy B, Rosemore J . Helicobacter pylori: ulcers and more: the beginning of an era. J Nutr. 2001; 131(10):2789S-2793S. DOI: 10.1093/jn/131.10.2789S. View

Biglar M, Mirzazadeh R, Asadi M, Sepehri S, Valizadeh Y, Sarrafi Y . Novel N,N-dimethylbarbituric-pyridinium derivatives as potent urease inhibitors: Synthesis, in vitro, and in silico studies. Bioorg Chem. 2019; 95:103529. DOI: 10.1016/j.bioorg.2019.103529. View

Daina A, Michielin O, Zoete V . SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717. PMC: 5335600. DOI: 10.1038/srep42717. View

10.

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

11.

Asgari M, Azizian H, Nazari Montazer M, Mohammadi-Khanaposhtani M, Asadi M, Sepehri S . New 1,2,3-triazole-(thio)barbituric acid hybrids as urease inhibitors: Design, synthesis, in vitro urease inhibition, docking study, and molecular dynamic simulation. Arch Pharm (Weinheim). 2020; 353(9):e2000023. DOI: 10.1002/ardp.202000023. View

12.

Salama N, Hartung M, Muller A . Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 2013; 11(6):385-99. PMC: 3733401. DOI: 10.1038/nrmicro3016. View

13.

Fagoonee S, Pellicano R . Helicobacter pylori: molecular basis for colonization and survival in gastric environment and resistance to antibiotics. A short review. Infect Dis (Lond). 2019; 51(6):399-408. DOI: 10.1080/23744235.2019.1588472. View

14.

Unsal-Tan O, Ozden K, Rauk A, Balkan A . Synthesis and cyclooxygenase inhibitory activities of some N-acylhydrazone derivatives of isoxazolo[4,5-d]pyridazin-4(5H)-ones. Eur J Med Chem. 2010; 45(6):2345-52. DOI: 10.1016/j.ejmech.2010.02.012. View

15.

Suerbaum S, Michetti P . Helicobacter pylori infection. N Engl J Med. 2002; 347(15):1175-86. DOI: 10.1056/NEJMra020542. View

16.

Kafarski P, Talma M . Recent advances in design of new urease inhibitors: A review. J Adv Res. 2018; 13:101-112. PMC: 6077125. DOI: 10.1016/j.jare.2018.01.007. View

17.

Korona-Glowniak I, Glowniak-Lipa A, Ludwiczuk A, Baj T, Malm A . The In Vitro Activity of Essential Oils against Growth and Urease Activity. Molecules. 2020; 25(3). PMC: 7037374. DOI: 10.3390/molecules25030586. View

18.

Graham D, Miftahussurur M . urease for diagnosis of infection: A mini review. J Adv Res. 2018; 13:51-57. PMC: 6077137. DOI: 10.1016/j.jare.2018.01.006. View

19.

Calvet X, Garcia N, Lopez T, Gisbert J, Gene E, Roque M . A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000; 14(5):603-9. DOI: 10.1046/j.1365-2036.2000.00744.x. View

20.

Rautelin H, Seppala K, RENKONEN O, Vainio U, Kosunen T . Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother. 1992; 36(1):163-6. PMC: 189246. DOI: 10.1128/AAC.36.1.163. View